Signal Genetics Reports Flat 2014 Revenues | GenomeWeb

NEW YORK (GenomeWeb) – Signal Genetics said in its Form 10-K today that its full-year 2014 revenue growth was flat year over year at $4.3 million. 

The molecular diagnostics firm also said that its net loss attributable to shareholders and company members was $7.9 million in 2014, compared to a net loss of $2.4 million in 2013. On a per-share basis, net loss retreated to $3.50 in 2014 compared to $12.23 in 2013. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.